Benralizumab reduced the number of eosinophils ... I agree with the researchers that these findings suggest that mechanisms beyond eosinophils may be behind eosinophilic gastritis.

Benralizumab is approved for the treatment ... suggests the co-existence of an eosinophil-independent pathogenic mechanism in many patients.” They continued, “As such, successful management ...

Benralizumab, an anti–interleukin-5 receptor ... The MESSINA trial raises several questions around the mechanisms behind the symptoms and inflammation seen in EoE, as well as targets for treatment.

Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL ...

A year's course of benralizumab injections has led to a ... of white blood cell and part of the immune system controlling the mechanism associated with allergy and asthma. Many patients with ...

Benralizumab is an eosinophil-depleting anti–interleukin-5 receptor α monoclonal antibody. The efficacy and safety of benralizumab in patients with eosinophilic esophagitis are unclear.

Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if used to treat acute asthma attacks, calling it the first major advance for this aspect of the disease in 50 ...

All received benralizumab 30 mg subcutaneously every ... lung function decline, through IL-13 mechanisms that FeNO fundamentally relates to," he said. "And you monitor lung function.

More patients with eosinophilic esophagitis experienced a histologic response with benralizumab (Fasenra) compared with placebo, despite similar levels of continuing symptoms in the two groups at ...

People taking benralizumab were significantly less likely to need further treatment for their asthma or COPD symptoms, a major clinical trial has shown ...